New hope for advanced cancer: first human trial of SHR-4712 begins
NCT ID NCT06993116
First seen Dec 15, 2025 · Last updated May 06, 2026 · Updated 22 times
Summary
This early-phase study tests a new drug called SHR-4712 in 15 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and how the body processes it. Participants receive the drug until their disease worsens or side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
Conditions
Explore the condition pages connected to this study.